Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles

Paloma Cejas(Dana-Farber Cancer Institute), Henry W. Long(Dana-Farber Cancer Institute), Christopher J. Sweeney(The University of Adelaide), Juan Moreno‐Rubio(Hospital La Paz Institute for Health Research), Víctor Moreno, Melissa Duarte(Dana-Farber Cancer Institute), Andrea Richardson(Brigham and Women's Hospital), Prakash K. Rao(Dana-Farber Cancer Institute), Damián García‐Olmo(Hospital Universitario Fundación Jiménez Díaz), Michelle S. Hirsch(Perinatal Institute), Lewyn Li(Dana-Farber Cancer Institute), Myles Brown(Harvard University), X. Shirley Liu(Harbin Medical University), Héctor Guadalajara(Hospital Universitario Fundación Jiménez Díaz), Ramesh A. Shivdasani(Harvard University), Chensheng W. Zhou(Dana-Farber Cancer Institute), Michaela Bowden(Brigham and Women's Hospital), Joaquim Bellmunt(Dana-Farber Cancer Institute), Nicholas K. O’Neill(Harvard University), Stephanie A. Mullane(Broad Institute), Jaime Feliú(Hospital Universitario La Paz), Emilio Burgos(Hospital Universitario Infanta Sofía), Marta Mendiola(Hospital Universitario La Paz)
Nature Medicine
April 25, 2016
10.1038/nm.4085
Cited by 76

Related Papers

Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k